Registered number
06567448
Ananta Medicare Ltd
Report and Financial Statements
31 December 2024
Ananta Medicare Ltd
Report and accounts
Contents
Page
Company information 1
Directors' report 2-3
Strategic report 4-5
Independent auditor's report 6-8
Income statement 9
Statement of comprehensive income 10
Statement of financial position 11
Statement of changes in equity 12
Statement of cash flows 13
Notes to the financial statements 14-20
Director's additional information 21-22
Ananta Medicare Ltd
Company Information
Directors
P K Jain
Secretary
S Kumar
Auditors
R Vora & Co Limited
6 Carlton Road
Romford
Essex
RM2 5AA
Bankers
ICICI Bank UK Plc
47 Ealing Road
Wembley
HA0 4BA
Registered office
Suite 1
2 Station Court
Townmead Road
Fulham
London SW6 2PY
Registered number
06567448
Ananta Medicare Ltd
Registered number: 06567448
Directors' Report
The directors present their report and financial statements for the year ended 31 December 2024.
Principal activities
The company's principal activity during the year continued to be that of wholesalers of pharmaceutical products.
Future developments
During the year ended 31 December 2023, the company invested £700,000 in obtaining know-how to gain access to registration with UK MHRA. The work on this project is currently ongoing. The Director is confident that the results of this investment will have revenue streams from 2028 onwards.
Foreign currency risk
The company is subject to foreign currency risk given that the functional currency of its operations being USD and the presentation currency being GBP. The company undertakes various mitigation strategies in an attempt to mitigate any losses from foreign currency conversion.
Credit risk
The company is subject to credit risk through its invoicing and lending. The company undertakes various mitigation strategies such as obtaining guarantees against debts and only trading with companies which have a known history of repayment.
Geo-political risk
The company is subject to geo-political risk due to its customer's main area of operations being Ukraine. At the time of writing, Ukraine is in the middle of a military conflict with Russia; this gives rise to unforseeable risks that would be expected when operating in a war zone. The company has limited ability to mitigate these risks but are looking at diversifying operations outside of Ukraine in the near future.
Dividends
The directors recommend a dividend for the year of £30,000 (2023: £30,000).
Events since the balance sheet date
The war in Ukraine has adversly impacted the company during the year and continues to after the reporting date. The Directors are optimistic that the market conditions will stabilise in the near future.
Directors
The following persons served as directors during the year:
P K Jain
Disclosure of information to auditors
Each person who was a director at the time this report was approved confirms that:
so far as he is aware, there is no relevant audit information of which the company's auditor is unaware; and
he has taken all the steps that he ought to have taken as a director in order to make himself aware of any relevant audit information and to establish that the company's auditor is aware of that information.
Directors' responsibilities
The directors are responsible for preparing the report and financial statements in accordance with applicable law and regulations.
Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (Financial Reporting Standard 102 and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these financial statements, the directors are required to:
select suitable accounting policies and then apply them consistently;
make judgements and estimates that are reasonable and prudent;
state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements;
prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.
The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.
Disclosure of information to auditors
Each person who was a director at the time this report was approved confirms that:
so far as he is aware, there is no relevant audit information of which the company's auditor is unaware; and
he has taken all the steps that he ought to have taken as a director in order to make himself aware of any relevant audit information and to establish that the company's auditor is aware of that information.
This report was approved by the board on 13 May 2025 and signed by its order.
Mr P Jain
Director
Ananta Medicare Ltd
Strategic Report
Introduction:

I am pleased to present the strategic report for the financial year 2024. This report provides an overview of the company's performance, considering the significant challenges posed by the ongoing war in Ukraine. Despite these adverse conditions, I am proud to announce that our company remained profitable and maintained a strong cash position throughout the year.

Financial Performance (KPI's):

Gross Profit Margin: GPM for 2024 was 7.89% (2023: 1.71%), an increase compared to the previous year. The company has remained profitable, despite the market conditions, through the contracts completed during the financial year. The GPM is high this year in relation to 2 very profitable contracts.

Net assets: I am pleased to report that the company's net assets have grown from £1,537,810 to £1,542,587. We are confident that we can continue to meet our financial obligations and remain liquid.

EBITDA: The compnay has shown strong performance through its EBITDA growing to £951,857 (2023: £701,988) an improvement of 36% from the prior year.

Principal Risks and Uncertainties:

Ukraine War
The ongoing conflict in Ukraine poses a significant risk to our business, primarily due to our primary customer base being located in that region. Management has diligently assessed this risk and acknowledges the considerable uncertainty surrounding its potential impact on the company. In light of this, management maintains a vigilant monitoring of the situation and remains cognizant of its potential consequences.

Credit Risk
The company is subject to credit risk through its invoicing and lending. The company undertakes various mitigation strategies such as obtaining guarantees against debts and only trading with companies which have a known history of repayment.

Logistics
In response to the logistical challenges arising from the war in Ukraine, management has proactively and meticulously implemented alternative arrangements for the transportation of goods. These measures were undertaken to guarantee the seamless fulfilment of customer orders placed throughout the financial year.

Regulation
In line with our steadfast commitment to risk management in a regulated industry, the company has diligently mitigated associated risks by ensuring that all goods sold have successfully undergone the requisite pharmacological tests and possess the necessary certifications. In order to sustain compliance, management remains vigilant in monitoring any changes to regulatory frameworks, thus enabling the company to promptly adapt and maintain adherence to prevailing regulations.

Outlook and Future Prospects:

The company has a positive outlook and anticipate a more profitable future, with a return to the normal course of business. However, it acknowledges the uncertainty surrounding the timing of this transition. Management have determination to navigate the current challenges and understands the need for flexibility and adaptability in the face of an unpredictable environment. Despite the unknown timeframe for the return to normalcy in the market, the company remains optimistic and committed to pursuing strategies that will drive profitability and position it for success once market conditions stabilize.

The company has invested £700,000 in the year ended 31 December 2023 in obtaining know-how to gain access to registration with UK MHRA. The Director is confident that the results of this investment will have revenue streams from 2028 onwards.
This report was approved by the board on 13 May 2025 and signed by its order.
Mr S Kumar
Secretary
Ananta Medicare Ltd
Independent auditor's report
to the member of Ananta Medicare Ltd
Opinion
We have audited the financial statements of Ananta Medicare Ltd (the 'company') for the year ended 31 December 2024 which comprise the Income Statement, the Statement of Comprehensive Income, the Statement of Financial Position, the Statement of Changes in Equity, the Statement of Cash Flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).
In our opinion the financial statements:
give a true and fair view of the state of the company's affairs as at 31 December 2024 and of its profit for the year then ended;
have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice;
have been prepared in accordance with the requirements of the Companies Act 2006.
Basis for opinion
We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor’s responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.
Material uncertainty related to going concern
We draw attention to note 16 in the financial statements that indicates the Russian invasion of the Company's Customer's country of operations. As stated in note 16, this event indicates that a material uncertainty exists that may cast significant doubt on the Company's ability to continue as a going concern. Our opinion is not modified in respect of this matter.
Other information
The other information comprises the information included in the annual report other than the financial statements and our auditor’s report thereon. The directors are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.
We have nothing to report in this regard.
Opinions on other matters prescribed by the Companies Act 2006
In our opinion, based on the work undertaken in the course of the audit:
the information given in the strategic report and the directors’ report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
the strategic report and the directors’ report have been prepared in accordance with applicable legal requirements.
Matters on which we are required to report by exception
In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the strategic report or the directors’ report.
We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:
adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
the financial statements are not in agreement with the accounting records and returns; or
certain disclosures of directors’ remuneration specified by law are not made; or
we have not received all the information and explanations we require for our audit.
Responsibilities of directors
As explained more fully in the directors’ responsibilities statement, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.
In preparing the financial statements, the directors are responsible for assessing the company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.
Auditor’s responsibilities for the audit of the financial statements
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.
Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:
Our audit is considered capable of detecting irregularities, including fraud by;

- Considering and obtaining evidence that the entity has complied with known, relevant laws and regulations.
- Developing an understanding of the legal and regulatory framework in which the entity operates and where the entity is based including relevant laws and regulations such as Data Protection Act 2018, Companies Act 2006, Corporation Tax Act 2010, Bribery Act 2010, Law of Ukraine "On Medicines" and Good Distribution Practice.
- Collecting evidence that the entity has complied with relevant regulatory framework.
- Assessing how the entity's financial statements may be susceptible to material fraud and factoring this into our audit approach.
- Developing an overall collective knowledge within the audit team of how instances of non-compliance with relevant laws and regulations can arise and how this can be identified.
- Investigating with informed management how they have developed controls to ensure fraud or irregularities are avoided and/or detected.
A further description of our responsibilities for the audit of the financial statements is available on the Financial Reporting Council’s website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor’s report.
Use of our report
This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.
Rajendra Vora
(Senior Statutory Auditor) 6 Carlton Road
for and on behalf of
R Vora & Co Limited Romford
Statutory Auditor Essex
RM2 5AA
15 May 2025
Ananta Medicare Ltd
Income Statement
for the year ended 31 December 2024
Notes 2024 2023
£ £
Turnover 2 4,213,374 12,987,260
Cost of sales (3,880,874) (12,765,487)
Gross profit 332,500 221,773
Administrative expenses (185,330) (154,228)
Other operating income 747,739 619,143
Operating profit 3 894,909 686,688
Interest receivable 372,411 288,296
Interest payable 5 (1,224,324) (906,017)
Profit on ordinary activities before taxation 42,996 68,967
Tax on profit on ordinary activities 6 (8,219) (19,014)
Profit for the financial year 34,777 49,953
Ananta Medicare Ltd
Statement of Comprehensive Income
for the year ended 31 December 2024
Notes 2024 2023
£ £
Profit for the financial year 34,777 49,953
Other comprehensive income
Total comprehensive income for the year 34,777 49,953
Ananta Medicare Ltd
Statement of Financial Position
as at 31 December 2024
Notes 2024 2023
£ £
Fixed assets
Intangible assets 7 629,885 685,885
Tangible assets 8 4,458 4,739
634,343 690,624
Current assets
Debtors 9 7,839,939 13,140,057
Long Term Loan 10 2,073,495 2,146,267
Cash at bank and in hand 4,576,125 8,732,464
14,489,559 24,018,788
Creditors: amounts falling due within one year 11 (13,575,405) (23,164,788)
Net current assets 914,154 854,000
Total assets less current liabilities 1,548,497 1,544,624
Provisions for liabilities
Deferred taxation 12 (5,910) (6,814)
Net assets 1,542,587 1,537,810
Capital and reserves
Called up share capital 13 100 100
Profit and loss account 14 1,542,487 1,537,710
Total equity 1,542,587 1,537,810
Mr P Jain
Director
Approved by the board on 13 May 2025
Ananta Medicare Ltd
Statement of Changes in Equity
for the year ended 31 December 2024
Share Share Other Profit Total
capital premium reserves and loss
account
£ £ £ £ £
At 1 January 2023 100 - - 1,517,757 1,517,857
Profit for the financial year - - - 49,953 49,953
Dividends - - - (30,000) (30,000)
At 31 December 2023 100 - - 1,537,710 1,537,810
At 1 January 2024 100 - - 1,537,710 1,537,810
Profit for the financial year - - - 34,777 34,777
Dividends - - - (30,000) (30,000)
At 31 December 2024 100 - - 1,542,487 1,542,587
Ananta Medicare Ltd
Statement of Cash Flows
for the year ended 31 December 2024
Notes 2024 2023
£ £
Operating activities
Profit for the financial year 34,777 49,953
Adjustments for:
Interest receivable (372,411) (288,296)
Interest payable 1,224,324 906,017
Tax on profit on ordinary activities 8,219 19,014
Depreciation 948 1,185
Amortisation of intangible assets 56,000 14,115
Decrease in stocks - 112,807
Decrease in debtors 5,300,283 52,232
(Decrease)/increase in creditors (10,722,315) 2,827,497
(4,470,175) 3,694,524
Interest received 311,591 165,987
Interest paid - (61)
Corporation tax paid 2,912 (46,162)
Cash (used in)/generated by operating activities (4,155,672) 3,814,288
Investing activities
Payments to acquire intangible fixed assets - (280,000)
Payments to acquire tangible fixed assets (667) -
Cash used in investing activities (667) (280,000)
Net cash (used)/generated
Cash (used in)/generated by operating activities (4,155,672) 3,814,288
Cash used in investing activities (667) (280,000)
Net cash (used)/generated (4,156,339) 3,534,288
Cash and cash equivalents at 1 January 8,732,464 5,198,176
Cash and cash equivalents at 31 December 4,576,125 8,732,464
Cash and cash equivalents comprise:
Cash at bank 4,576,125 8,732,464
Ananta Medicare Ltd
Notes to the Accounts
for the year ended 31 December 2024
1 Summary of significant accounting policies
Basis of preparation
The financial statements have been prepared under the historical cost convention and in accordance with FRS 102, The Financial Reporting Standard applicable in the UK and Republic of Ireland.
Going Concern
After reviewing the company’s expectations and future trading conditions, the directors have a reasonable expectation that the company has adequate resources to continue in operational
existence for the foreseeable future. The company therefore continues to adopt the going concern basis of accounting in preparing its financial statements.
Turnover
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services. Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.
Intangible fixed assets
Intangible fixed assets are measured at cost less accumulative amortisation and any accumulative impairment losses.
Amortisation is provided to write off the cost of the asset evenly over its expected useful life from the point of being brought into use.
Tangible fixed assets
Tangible fixed assets are measured at cost less accumulative depreciation and any accumulative impairment losses. Depreciation is provided on all tangible fixed assets, other than freehold land, at rates calculated to write off the cost, less estimated residual value, of each asset evenly over its expected useful life, as follows:
Fixtures, fittings, tools and equipment 20% per annum reducing balance
Debtors
Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.
Creditors
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.
Taxation
A current tax liability is recognised for the tax payable on the taxable profit of the current and past periods. A current tax asset is recognised in respect of a tax loss that can be carried back to recover tax paid in a previous period. Deferred tax is recognised in respect of all timing differences between the recognition of income and expenses in the financial statements and their inclusion in tax assessments. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference, except for revalued land and investment property where the tax rate that applies to the sale of the asset is used. Current and deferred tax assets and liabilities are not discounted.
Foreign currency translation
Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction.

At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.
Pensions
Contributions to defined contribution plans are expensed in the period to which they relate.
2 Analysis of turnover 2024 2023
£ £
Sale of goods 4,213,374 12,987,260
By geographical market:
UK 12,598 -
Rest of world 4,200,776 12,987,260
4,213,374 12,987,260
3 Operating profit 2024 2023
£ £
This is stated after charging:
Depreciation of owned fixed assets 948 1,185
Amortisation of know-how 56,000 14,115
Operating lease rentals - land and buildings 13,600 13,600
Auditors' remuneration for audit services 11,000 11,000
4 Staff costs 2024 2023
£ £
Wages and salaries 41,400 41,400
Directors Emoluments - -
Social security costs - -
Other pension costs 1,782 713
43,182 42,113
Average number of employees during the year Number Number
Administration 2 2
2 2
5 Interest payable 2024 2023
£ £
Trade creditors 1,224,324 906,017
6 Taxation 2024 2023
£ £
Analysis of charge in period
Current tax:
UK corporation tax on profits of the period - 2,846
Overseas tax charges 9,123 9,189
9,123 12,035
Deferred tax:
Origination and reversal of timing differences (904) 6,979
Tax on profit on ordinary activities 8,219 19,014
Factors affecting tax charge for period
The differences between the tax assessed for the period and the standard rate of corporation tax are explained as follows:
2024 2023
£ £
Profit on ordinary activities before tax 42,996 68,967
Standard rate of corporation tax in the UK 25% 19%
£ £
Profit on ordinary activities multiplied by the standard rate (25%) of corporation tax for 2024 financial year 10,749 12,515
Profit on ordinary activities multiplied by the standard rate (19%) of corporation tax for 2023 financial year - 3,231
Effects of:
Expenses not deductible for tax purposes 14,000 (14,115)
Capital allowances for period in excess of depreciation (171) 1,215
Trading losses utilised (14,792)
Marginal Relief (663)
Current tax charge for period 9,123 12,035
7 Intangible fixed assets £
Know-how:
Cost
At 1 January 2024 700,000
At 31 December 2024 700,000
Amortisation
At 1 January 2024 14,115
Provided during the year 56,000
At 31 December 2024 70,115
Carrying amount
At 31 December 2024 629,885
At 31 December 2023 685,885
Know-how is being written off in equal annual instalments over its estimated economic life of 5 years.
The amounts capitalised is for the contracted cost to acquire know-how.
8 Tangible fixed assets
Fixtures, fittings, tools and equipment
At cost
£
Cost or valuation
At 1 January 2024 283,792
Additions 667
At 31 December 2024 284,459
Depreciation
At 1 January 2024 279,053
Charge for the year 948
At 31 December 2024 280,001
Carrying amount
At 31 December 2024 4,458
At 31 December 2023 4,739
9 Debtors 2024 2023
£ £
Trade debtors 7,839,939 13,139,757
Prepayments and accrued income - 300
7,839,939 13,140,057
10 Long Term Loan 2024 2023
£ £
Long Term Loan 2,073,495 2,146,267
The company has made an unsecured loan to Alisha Estate Ltd which is owned by P Jain. The total loan facility agreed is for $5m and repayable by 31st December 2030. Interest rate chargeable on the loan is at 3% pa. As at 31st December 2024 £2,073,495 (2023: £2,146,266) was outstanding to the company.
11 Creditors: amounts falling due within one year 2024 2023
£ £
Trade creditors 13,139,162 22,692,389
Corporation tax 61 61
Other taxes and social security costs 178 926
Other creditors 422,906 457,814
Accruals and deferred income 13,098 13,598
13,575,405 23,164,788
12 Deferred taxation 2024 2023
£ £
Capital allowances - timing difference 5,910 6,814
2024 2023
£ £
At 1 January 6,814 (165)
(Credited)/charged to the profit and loss account (904) 6,979
At 31 December 5,910 6,814
13 Share capital Nominal 2024 2024 2023
value Number £ £
Allotted, called up and fully paid:
Ordinary shares £1 each 100 100 100
14 Profit and loss account 2024 2023
£ £
At 1 January 1,537,710 1,517,757
Profit for the financial year 34,777 49,953
Dividends (30,000) (30,000)
At 31 December 1,542,487 1,537,710
15 Dividends 2024 2023
£ £
Dividends on ordinary shares (note 14) 30,000 30,000
16 Continued events after the reporting date
The ongoing Russian invasion of Ukraine, which continues beyond the reporting date, continues to significantly influence the business. Given that the company's predominant customer base resides in Ukraine, this has introduced a degree of uncertainty concerning the company's continued viability. Consequently, the Directors are currently exploring strategic moves into alternative geographic markets, notably the United States, as a proactive measure to mitigate the emerging risks.

It is important to note that the financial ramifications of this event cannot be reasonably quantified at this juncture. Despite these challenges, the company remains operational and committed to sustaining its operations, albeit at a reduced capacity. To adapt to the evolving situation, we have made necessary logistical adjustments pertaining to the transportation of goods.
17 Other financial commitments
Total future minimum lease payments under non-cancellable operating leases:
Land and buildings Land and buildings Other Other
2024 2023 2024 2023
£ £ £ £
Falling due:
within one year 12,000 12,000 - -
within two to five years 12,000 - - -
24,000 12,000 - -
18 Related party transactions
Mr P Jain owns 100% of the interest in the following 2 companies.
1. Alisha Estates Ltd - (Ukraine) - The company made an unsecured loan arrangement of $5million and as at 31st December 2024 the amount lent was £2,073,495 (2023 - £2,146,266) owed to the company as a long-term debtor.
2. Vita Sun Ltd - (UK) - Company owned by P Jain - payments were made to the company during the year to the value of $9,985.20 (2023: $10,000) and the balance outstanding as at 31st December 2024 was £23,692.86 (2023: £31,896) owed by the company to the related party.
Other related party transactions not with companies:
The company paid rent on premises in UK which are owned by Mr P Jain £12,000 - (2023- £13,600)
19 Controlling party
Mr P Jain is the controlling party owning 100% of the shares in the business
20 Presentation currency
The financial statements are presented in Sterling being a UK company. The functional currency is USD.
21 Legal form of entity and country of incorporation
Ananta Medicare Ltd is a private company limited by shares and incorporated in England.
22 Principal place of business
The address of the company's principal place of business and registered office is:
Suite 1
2 Station Court
Townmead Road
Fulham
London SW6 2PY
Ananta Medicare Ltd 06567448 false 2024-01-01 2024-12-31 2024-12-31 VT Final Accounts April 2025 Mr P Jain 06567448 2023-01-01 2023-12-31 06567448 bus:AllOrdinaryShares core:RetainedEarningsAccumulatedLosses 2023-01-01 2023-12-31 06567448 countries:UnitedKingdom 2023-01-01 2023-12-31 06567448 countries:OtherCountriesRegions 2023-01-01 2023-12-31 06567448 core:OwnedAssets 2023-01-01 2023-12-31 06567448 core:LandBuildingsUnderOperatingLeases 2023-01-01 2023-12-31 06567448 1 2023-01-01 2023-12-31 06567448 bus:OrdinaryShareClass1 2023-01-01 2023-12-31 06567448 core:RetainedEarningsAccumulatedLosses 2023-01-01 2023-12-31 06567448 core:WithinOneYear 2023-12-31 06567448 core:ShareCapital 2023-12-31 06567448 core:RetainedEarningsAccumulatedLosses 2023-12-31 06567448 core:AcceleratedTaxDepreciationDeferredTax 2023-12-31 06567448 core:WithinOneYear core:LandBuildingsUnderOperatingLeases 2023-12-31 06567448 core:WithinOneYear core:PlantEquipmentOtherAssetsUnderOperatingLeases 2023-12-31 06567448 core:BetweenOneFiveYears core:LandBuildingsUnderOperatingLeases 2023-12-31 06567448 core:BetweenOneFiveYears core:PlantEquipmentOtherAssetsUnderOperatingLeases 2023-12-31 06567448 core:AllPeriods core:LandBuildingsUnderOperatingLeases 2023-12-31 06567448 core:AllPeriods core:PlantEquipmentOtherAssetsUnderOperatingLeases 2023-12-31 06567448 2022-12-31 06567448 core:ShareCapital 2022-12-31 06567448 core:SharePremium 2022-12-31 06567448 core:OtherReservesSubtotal 2022-12-31 06567448 core:RetainedEarningsAccumulatedLosses 2022-12-31 06567448 2024-01-01 2024-12-31 06567448 bus:PrivateLimitedCompanyLtd 2024-01-01 2024-12-31 06567448 bus:Audited 2024-01-01 2024-12-31 06567448 bus:Director1 2024-01-01 2024-12-31 06567448 1 2024-01-01 2024-12-31 06567448 bus:CompanySecretary1 2024-01-01 2024-12-31 06567448 core:RetainedEarningsAccumulatedLosses 2024-01-01 2024-12-31 06567448 bus:AllOrdinaryShares core:RetainedEarningsAccumulatedLosses 2024-01-01 2024-12-31 06567448 1 2024-01-01 2024-12-31 06567448 2 2024-01-01 2024-12-31 06567448 countries:UnitedKingdom 2024-01-01 2024-12-31 06567448 countries:OtherCountriesRegions 2024-01-01 2024-12-31 06567448 core:OwnedAssets 2024-01-01 2024-12-31 06567448 core:LandBuildingsUnderOperatingLeases 2024-01-01 2024-12-31 06567448 1 2024-01-01 2024-12-31 06567448 core:Goodwill 2024-01-01 2024-12-31 06567448 core:FurnitureFittingsToolsEquipment 2024-01-01 2024-12-31 06567448 bus:OrdinaryShareClass1 2024-01-01 2024-12-31 06567448 countries:England 2024-01-01 2024-12-31 06567448 bus:FRS102 2024-01-01 2024-12-31 06567448 bus:FullAccounts 2024-01-01 2024-12-31 06567448 2024-12-31 06567448 core:WithinOneYear 2024-12-31 06567448 core:ShareCapital 2024-12-31 06567448 core:RetainedEarningsAccumulatedLosses 2024-12-31 06567448 core:SharePremium 2024-12-31 06567448 core:OtherReservesSubtotal 2024-12-31 06567448 core:Goodwill 2024-12-31 06567448 core:FurnitureFittingsToolsEquipment 2024-12-31 06567448 core:AcceleratedTaxDepreciationDeferredTax 2024-12-31 06567448 bus:OrdinaryShareClass1 2024-12-31 06567448 core:WithinOneYear core:LandBuildingsUnderOperatingLeases 2024-12-31 06567448 core:WithinOneYear core:PlantEquipmentOtherAssetsUnderOperatingLeases 2024-12-31 06567448 core:BetweenOneFiveYears core:LandBuildingsUnderOperatingLeases 2024-12-31 06567448 core:BetweenOneFiveYears core:PlantEquipmentOtherAssetsUnderOperatingLeases 2024-12-31 06567448 core:AllPeriods core:LandBuildingsUnderOperatingLeases 2024-12-31 06567448 core:AllPeriods core:PlantEquipmentOtherAssetsUnderOperatingLeases 2024-12-31 06567448 2023-12-31 06567448 core:SharePremium 2023-12-31 06567448 core:OtherReservesSubtotal 2023-12-31 06567448 core:Goodwill 2023-12-31 06567448 core:FurnitureFittingsToolsEquipment 2023-12-31 iso4217:GBP iso4217:GBP xbrli:shares xbrli:pure xbrli:shares